Shire PLC (SHPG): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Shire ( SHPG) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.4%. By the end of trading, Shire rose $1 (1.1%) to $91.98 on average volume. Throughout the day, 305,492 shares of Shire exchanged hands as compared to its average daily volume of 320,000 shares. The stock ranged in a price between $91.52-$92.21 after having opened the day at $92.07 as compared to the previous trading day's close of $90.98. Other companies within the Health Care sector that increased today were: Atossa Genetics ( ATOS), up 34.3%, Pacific Biosciences of California ( PACB), up 15.4%, KYTHERA Biopharmaceuticals ( KYTH), up 13.7%, and NPS Pharmaceuticals ( NPSP), up 9.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $17.26 billion and is part of the drugs industry. The company has a P/E ratio of 23.4, above the S&P 500 P/E ratio of 17.7. Shares are down 1.3% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the negative front, Affymax ( AFFY), down 64%, Star Scientific ( STSI), down 17.2%, Rockwell Medical ( RMTI), down 15.9%, and Savient Pharmaceuticals ( SVNT), down 14.8%, were all laggards within the health care sector with Herbalife ( HLF) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.

null

More from Markets

50 Stocks Goldman Sachs Thinks Can Triumph Over Labor Inflation

50 Stocks Goldman Sachs Thinks Can Triumph Over Labor Inflation

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China